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Abbreviations Used in This Report*
DT Diphtheria and tetanus toxoids vaccine (for children)
DTaP Diphtheria and tetanus toxoids and acellular pertussis vaccine
DTaP-Hib Diphtheria and tetanus toxoids and acellular pertussis and
Haemophilus influenzae type b vaccine
DTP Diphtheria and tetanus toxoids and pertussis vaccine (unspecified
pertussis antigens)
DTP-Hib Diphtheria and tetanus toxoids and pertussis and Haemophilus
influenzae type b vaccine (unspecified pertussis antigens)
DTwP Diphtheria and tetanus toxoids and whole-cell pertussis vaccine
DTwP-Hib Diphtheria and tetanus toxoids and whole-cell pertussis and
Haemophilus influenzae type b vaccine
HepA Hepatitis A vaccine
HepB Hepatitis B vaccine
Hib Haemophilus influenzae type b conjugate vaccine
 PRP-OMP Hib polyribosylribitol phosphate polysaccharide conjugated to a
meningococcal outer membrane protein
 PRP-T Hib polyribosylribitol phosphate polysaccharide conjugated to tetanus
toxoid
 HbOC Hib oligosaccharides conjugated to diphtheria CRM197 toxin protein
 PRP-D Hib polyribosylribitol phosphate polysaccharide conjugated to
diphtheria toxoid
Hib-HepB Haemophilus influenzae type b and hepatitis B vaccine
Hib-HepB-IPV Haemophilus influenzae type b, hepatitis B, and trivalent
inactivated polio vaccine
INF Influenza vaccine
IPV Trivalent inactivated polio vaccine (killed Salk type)
Me Measles vaccine
Me-Rub Measles and rubella vaccine
MenCon Meningococcal (Neisseria meningitidis) conjugate vaccine
MenPS Meningococcal (Neisseria meningitidis) polysaccharride vaccine
MMR Measles-mumps-rubella vaccine
MMR-Var Measles-mumps-rubella and varicella vaccine
Mu Mumps vaccine
Mu-Rub Mumps and rubella vaccine
OPV Trivalent oral polio vaccine (live Sabin type)
PnuCon Pneumococcal (Streptococcus pneumoniae) conjugate vaccine
PnuPS Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccine
Rub Rubella vaccine
Rv Rotavirus vaccine
Td Tetanus and diphtheria toxoids vaccine (for adolescents and adults)
TT Tetanus toxoid vaccine
Var Varicella (chickenpox) vaccine
*Excludes some pentavalent and larger combinations listed in Appendix A. As of publication
date, some vaccine combinations listed are not licensed or approved for persons of all ages
in the United States.
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DTaP
diphtheria and tetanus toxoids and 
acellular pertussis vaccine
ACEL-IMUNE® (WLV)
Certiva  (NAV, distributed by ALI)
Infanrix® (SBB, distributed by SB)
Tripedia® (CON, distributed by PMC)
DTaP-Hib
diphtheria and tetanus toxoids and 
acellular pertussis and Haemophilus
influenzae type b vaccine
TriHIBit®* (ActHIB® Hib reconstituted with
 Tripedia® DTaP; distributed by PMC)
DTwP
diphtheria and tetanus toxoids and 
whole-cell pertussis vaccine
Tri-Immunol® (WLV)†
(Generic products from other
 manufacturers)
DTwP-Hib
diphtheria and tetanus toxoids and whole-
cell pertussis and Haemophilus influenzae
type b vaccine
ActHIB® Hib reconstituted with DTwP
 (CON; distributed by PMC)
TETRAMUNE® (WLV)
HepA
hepatitis A vaccine
HAVRIX® (SBB, distributed by SB)
VAQTA® (MRK)
HepB
hepatitis B vaccine
ENGERIX-B® (SBB, distributed by SB)
RECOMBIVAX HB® (MRK)
Hib
Haemophilus influenzae type b conjugate
vaccine
HbOC – oligosaccharides conjugated to
diphtheria CRM197 toxin protein
HibTITER® (WLV)
PRP-OMP – polyribosylribitol phosphate
polysaccharide conjugated to a
meningococcal outer membrane protein
PedvaxHIB® (MRK)
PRP-T – polyribosylribitol phosphate poly-
saccharide conjugated to tetanus toxoid
ActHIB® (PMSV, distributed by CON, PMC)
OmniHIB  (PMSV, distributed by SB)
PRP-D – polyribosylribitol phosphate poly-
saccharide conjugated to diphtheria
toxoid
ProHIBiT® (CON, distributed by PMC)
Hib-HepB
Haemophilus influenzae type b and hepatitis
B vaccine
COMVAX® (Hib component = PRP-OMP)
 (MRK)
IPV
trivalent inactivated polio vaccine
(killed Salk type)
IPOL® (PMSV, distributed by CON, PMC)
MMR
measles-mumps-rubella vaccine
M-M-R® II (MRK)
OPV
trivalent oral polio vaccine (live Sabin type)
Orimune® (WLV)
Rv
rotavirus vaccine (live, oral, tetravalent)
RotaShield® (WLV)
Var
Varicella (chickenpox) vaccine
VARIVAX® (MRK)
Product Brand Names and Manufacturers/Distributors
for Principal Childhood Vaccine Types
* As of April 10, 1999, TriHIBit® was licensed only for the fourth dose recommended at age 15–18 months
in the vaccination series.
†Manufacture discontinued.
Abbreviations: ALI=Ross Products Division, Abbott Laboratories Inc.; CON=Connaught Laboratories, Inc.;
MRK=Merck & Co., Inc.; NAV=North American Vaccine, Inc.; PMC=Pasteur Mérieux Connaught; PMSV=Pas-
teur Mérieux Sérums & Vaccins, S.A.; SBB=SmithKline Beecham Biologicals; SB=SmithKline Beecham
Pharmaceuticals; WLV=Lederle Laboratories Division of American Cyanamid Company (marketed by Wyeth-
Lederle Vaccines, Wyeth-Ayerst Laboratories).
vi MMWR May 14, 1999
Combination Vaccines for Childhood Immunization
Recommendations of the Advisory Committee on
Immunization Practices (ACIP), the American Academy of
Pediatrics (AAP), and the American Academy of Family
Physicians (AAFP)
Summary
An increasing number of new and improved vaccines to prevent childhood
diseases are being introduced. Combination vaccines represent one solution to
the problem of increased numbers of injections during single clinic visits. This
statement provides general guidance on the use of combination vaccines and
related issues and questions.
To minimize the number of injections children receive, parenteral combina-
tion vaccines should be used, if licensed and indicated for the patient’s age,
instead of their equivalent component vaccines. Hepatitis A, hepatitis B, and
Haemophilus influenzae type b vaccines, in either monovalent or combination
formulations from the same or different manufacturers, are interchangeable for
sequential doses in the vaccination series. However, using acellular pertussis
vaccine product(s) from the same manufacturer is preferable for at least the first
three doses, until studies demonstrate the interchangeability of these vaccines.
Immunization providers should stock sufficient types of combination and mono-
valent vaccines needed to vaccinate children against all diseases for which
vaccines are recommended, but they need not stock all available types or brand-
name products. When patients have already received the recommended
vaccinations for some of the components in a combination vaccine, administer-
ing the extra antigen(s) in the combination is often permissible if doing so will
reduce the number of injections required.
To overcome recording errors and ambiguities in the names of vaccine com-
binations, improved systems are needed to enhance the convenience and
accuracy of transferring vaccine-identifying information into medical records
and immunization registries. Further scientific and programmatic research is
needed on specific questions related to the use of combination vaccines.
INTRODUCTION
The introduction of vaccines for newly preventable diseases poses a challenge for
their incorporation into an already complex immunization schedule. To complete the
1999 Recommended Childhood Immunization Schedule in the United States (1,2 ), a
minimum of 13 separate injections are needed to immunize a child from birth to age 6
years, using vaccines licensed in the United States as of April 10, 1999. During some
office or clinic visits, the administration of three or four separate injections can be
indicated.
Combination vaccines merge into a single product antigens that prevent different
diseases or that protect against multiple strains of infectious agents causing the same
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disease. Thus, they reduce the number of injections required to prevent some dis-
eases. Combination vaccines available for many years include diphtheria and tetanus
toxoids and whole-cell pertussis vaccine (DTwP); measles-mumps-rubella vaccine
(MMR); and trivalent inactivated polio vaccine (IPV). Combinations licensed in recent
years in the United States include diphtheria and tetanus toxoids and acellular pertus-
sis vaccine (DTaP) (3–6 ), DTwP-Haemophilus influenzae type b (Hib) vaccine
(DTwP-Hib) (7,8 ), DTaP-Hib* (9 ), and Hib-hepatitis B (HepB) vaccine (Hib-HepB) (10 ).
In the future, combination vaccines might include increasing numbers of components
in different arrays to protect against these and other diseases, including hepatitis A,
Neisseria meningitidis, Streptococcus pneumoniae, and varicella (Appendix A) (11 ).
Combination vaccines have some drawbacks. Chemical incompatibility or immu-
nologic interference when different antigens are combined into one vaccine could be
difficult to overcome (12–16 ). Vaccine combinations that require different schedules
might cause confusion and uncertainty when children are treated by multiple vaccine
providers who use different products. The trend to develop combination products
could encourage vaccine companies to merge to acquire the needed intellectual prop-
erty (17 ). Competition and innovation might be reduced if companies with only a few
vaccine antigens are discouraged from developing new products.
This report, published simultaneously by the Advisory Committee on Immunization
Practices (ACIP) (18 ), the American Academy of Pediatrics (AAP) (19 ) and the Ameri-
can Academy of Family Physicians (AAFP) (20 ), provides general recommendations
for the optimal use of existing and anticipated parenteral combination vaccines, along
with relevant background, rationale, and discussion of questions raised by the use of
these products. Principal recommendations are classified by the strength and quality
of evidence supporting them (Appendix B) (21–24 ).
PREFERENCE FOR COMBINATION VACCINES
The use of licensed combination vaccines is preferred over separate injection of
their equivalent component vaccines. Only combinations approved by the U.S. Food
and Drug Administration (FDA) should be used.
Rationale
The use of combination vaccines is a practical way to overcome the constraints of
multiple injections, especially for starting the immunization series for children behind
schedule. The use of combination vaccines might improve timely vaccination cover-
age. Some immunization providers and parents object to administering more than
two or three injectable vaccines during a single visit because of a child’s fear of nee-
dles and pain (25–30 ) and because of unsubstantiated concerns regarding safety
(31,32 ).
Other potential advantages of combination vaccines include a) reducing the cost of
stocking and administering separate vaccines, b) reducing the cost for extra health-
care visits, and c) facilitating the addition of new vaccines into immunization
*As of April 10, 1999, DTaP-Hib vaccine was licensed only for the fourth dose recommended
at age 15–18 months in the vaccination series.
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programs. The price of a new combination vaccine can sometimes exceed the total
price of separate vaccines for the same diseases. However, the combination vaccine
might represent a better economic value if one considers the direct and indirect costs
of extra injections, delayed or missed vaccinations, and additional handling and stor-
age (11 ).
Combining Separate Vaccines Without FDA Approval
Immunization providers should not combine separate vaccines into the same syr-
inge to administer together unless such mixing is indicated for the patient’s age on the
respective product label inserts approved by the FDA. The safety, immunogenicity,
and efficacy of such unlicensed combinations are unknown (33 ).
INTERCHANGEABILITY OF VACCINE PRODUCTS
In general, vaccines from different manufacturers that protect against the same dis-
ease may be administered interchangeably in sequential doses in the immunization
series for an individual patient (e.g., hepatitis A [HepA], HepB, and Hib). However, until
data supporting interchangeability of acellular pertussis vaccines (e.g., DTaP) are
available, vaccines from the same manufacturer should be used, whenever feasible,
for at least the first three doses in the pertussis series. Immunization providers who
cannot determine which DTaP vaccine was previously administered, or who do not
have the same vaccine, should use any of the licensed acellular pertussis products to
continue the immunization series.
Interchangeability of Formulations
The FDA generally licenses a combination vaccine based on studies indicating that
the product’s immunogenicity (or efficacy) and safety are comparable with or equiva-
lent to monovalent or combination products licensed previously (16,34 ). FDA
approval also generally indicates that a combination vaccine may be used inter-
changeably with monovalent formulations and other combination products with
similar component antigens produced by the same manufacturer to continue the vac-
cination series. For example, DTaP, DTaP-Hib, and future DTaP-combination vaccines
(Appendix A) that contain similar acellular pertussis antigens from the same manufac-
turer may be used interchangeably, if approved for the patient’s age.
Interchangeability of Vaccines From Different Manufacturers
The licensure of a vaccine does not necessarily indicate that interchangeability with
products of other manufacturers has been demonstrated. Such data are ascertained
and interpreted more easily for diseases with known correlates of protective immunity
(e.g., specific antibodies). For diseases without such surrogate laboratory markers,
field efficacy (phase III) trials or postlicensure surveillance generally are required to
determine protection (35,36 ).
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Diseases With Serologic Correlates of Immunity
Studies of serologic responses that have been correlated with protection against
specific diseases support the interchangeability of vaccines from different manufac-
turers for HepA, HepB, and Hib.
Preliminary data indicate that the two hepatitis A vaccine products currently li-
censed in the United States (37 ) may be used interchangeably (38 ) (Merck & Co., Inc.,
unpublished data, 1998). Hepatitis B vaccine products (i.e., HepB and Hib-HepB if age-
appropriate) also may be interchanged for any doses in the hepatitis B series (39 ).
Based on subsequent data (40–42 ), the guidelines for Haemophilus influenzae type
b disease (7,43 ) were updated in the 1998 Recommended Childhood Immunization
Schedule (44–47 ) to indicate that different Hib vaccine products from several manu-
facturers may be used interchangeably for sequential doses of the vaccination series.
A PRP-OMP Hib (Hib vaccine with a polyribosylribitol phosphate polysaccharide con-
jugated to a meningococcal outer membrane protein) or a PRP-OMP Hib-HepB
vaccine might be administered in a series with HbOC Hib (Hib vaccine with oligosac-
charides conjugated to diphtheria CRM197 toxin protein) or with PRP-T Hib
(polyribosylribitol phosphate polysaccharide conjugated to tetanus toxoid). In such
cases, the recommended number of doses to complete the series is determined by the
HbOC or PRP-T product, not by the PRP-OMP vaccine (1,2 ). For example, if PRP-OMP
Hib is administered for the first dose at age 2 months and another product is adminis-
tered at age 4 months, a third dose of any of the licensed Hib vaccines is
recommended at age 6 months to complete the primary series.
Diseases Without Serologic Correlates of Immunity
Despite extensive research, no serologic correlates of immunity have been identi-
fied for pertussis. Limited data exist concerning the safety, immunogenicity, or
efficacy of administering acellular pertussis vaccines (e.g., DTaP or DTaP-Hib) from
different manufacturers between the fourth (at age 15–18 months) and fifth (at age 4–6
years) doses in the vaccination series (48 ). No data are available regarding the inter-
changeability of acellular pertussis products from different manufacturers for the first
three pertussis doses scheduled at ages 2, 4, and 6 months. Thus, use of the same
manufacturer’s acellular pertussis vaccine product(s) is preferred for at least the first
three doses in the series (5,49 ).
VACCINE SUPPLY
Immunization clinics and providers should maintain a supply of vaccines that will
protect children from all diseases specified in the current Recommended Childhood
Immunization Schedule (1,2 ). This responsibility can be fulfilled by stocking several
combination and monovalent vaccine products. However, not stocking all available
combination and monovalent vaccines or multiple products of each is acceptable.
New and potential combination vaccines can contain different but overlapping
groups of antigens (Appendix A). Thus, not all such vaccines would need to be avail-
able for the age-appropriate vaccination of children. Those responsible for childhood
vaccination can stock several vaccine types and products, or they may continue
to stock a limited number, as long as they prevent all diseases recommended in the
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OBJECTIVE
This MMWR  provides recommendations and guidance for the use of combination vaccines in children. This
statement was developed by working groups and representatives of the ACIP, AAP, and AAFP, who convened in
December 1996 and reached consensus in 1998. These recommendations should guide clinical practice for the
care of children and help shape future programs and clinical research agendas. Upon completing this educa-
tional activity, the reader should understand the advantages and disadvantages of combination vaccines,
which products may be interchanged for sequential doses, and the rationale for and limits of administering
extra doses of vaccine antigens.
ACCREDITATION
Continuing Medical Education (CME): This activity has been planned and implemented in accordance with the
Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) by CDC. CDC
is accredited by the ACCME to provide continuing medical education for physicians. CDC designates this edu-
cational activity for a maximum of 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
Continuing Education Units (CEU): CDC awards 0.1 hour of CEUs. This activity has been structured following
the International Association for Continuing Education and Training (IACET) Criteria and Guidelines and there-
fore is awarding CEUs. The CEU is a nationally recognized unit designed to provide a record of an individual’s
continuing education accomplishments.
Continuing Nursing Education (CNE) Credit: This activity for 1.2 contact hours is provided by CDC, which is
accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s
(ANCC) Commission on Accreditation.
EXPIRATION — May 14, 2000
The response form must be completed and returned electronically, by fax, or by mail, postmarked no later than
1 year from the publication date of this report, for eligibility to receive continuing education credit.
INSTRUCTIONS 
1. Read this MMWR (Vol. 48, RR-5 ), which contains the correct answers to the questions beginning on the
next page.
2. Complete all registration information on the response form, including your name, mailing address,
phone number, and e-mail address, if available.
3. Indicate whether you are registering for Continuing Medical Education (CME), Continuing Education
Unit (CEU), or Continuing Nursing Education (CNE) credit.
4. Select your answers to the questions, and mark the corresponding letters on the response form. To
receive continuing education credit, you must answer all of the questions. Questions with more than
one answer will instruct you to “indicate all that are true.”
5. Sign and date the response form.
6. Return the response form, or a photocopy of the form, no later than May 14, 2000, to CDC by one of the
following methods:
Internet: <http://www2.cdc.gov/cep/> Mail: MMWR CE Credit
Fax: 404-639-4198 Office of Scientific and Health Communications
Epidemiology Program Office — MS C08
Centers for Disease Control and Prevention
1600 Clifton Road, N.E.
Atlanta, GA 30333
If you answer all of the questions, you will receive an award letter for 1 hour of CME credit, 0.1 hour of
CEU credit, or 1.2 hours of CNE credit within 90 days. No fees are charged for participating in this
continuing education activity.
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To receive continuing education credit, please answer all of the following questions.
1. Which of the following are combination vaccines?  (Indicate all that are true.)
A. Hepatitis A vaccine (HepA).
B. Haemophilus influenzae type b vaccine (Hib).
C. Inactivated polio vaccine (IPV).
D. Tetanus and diphtheria toxoids vaccine (Td).
2. Which of the following are advantages of using a combination vaccine instead of
separate monovalent vaccines for the same diseases?  (Indicate all that are true.)
A. Lower purchase price for the combination compared with the purchase of sepa-
rate vaccines for the individual components.
B. Reduced pain and needle phobia caused when multiple injectable vaccines are
administered during a single visit.
C. Decreased handling and stocking compared with separate vaccines.
D. Facilitation of the introduction of new vaccines into immunization programs.
3. Combining two separate vaccines into the same syringe for administration to-
gether is allowable . . .  (Indicate all that are true.)
A. only when a child would otherwise require ≥4 injections.
B. only when FDA-approved for the specific vaccines and age of the child.
C. only when a child is aged ≥12 months.
D. only when the risk for missed opportunity to vaccinate outweighs the risk for
possible adverse reactions.
4. For which of the following vaccines may products from different manufacturers
be interchanged routinely for sequential doses in the series for a patient?  (Indi-
cate all that are true.)
A. Hepatitis A vaccine (HepA).
B. Hepatitis B vaccine (HepB).
C  Haemophilus influenzae type b vaccine (Hib).
D. Diptheria and tetanus toxoids and acellular pertussis vaccine (DTaP).
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5. Which vaccine antigens have caused local adverse reactions in some cases when
administered to persons still immune from prior vaccinations?  (Indicate all that
are true.)
A. Measles (Me, or in MMR).
B. Tetanus toxoid-containing vaccines.
C. Hepatitis B (HepB).
D. Pneumococcal polysaccharide vaccine (PnuPS).
6. According to 1994 data, the percentage of U.S. children who received vaccina-
tions from two or more immunization providers during the first 2 years of life
was . . . (Choose the one correct answer.)
A. 5%.
B. 10%.
C. 25%.
D. 50%.
7. Immunization providers are required by law to document in medical records
which of the following information for most vaccines administered to children?
(Indicate all that are true.)
A. Vaccine identity (type and manufacturer or brandname).
B. Date of administration.
C. Vaccine expiration date.
D. Vaccine lot number.
8. Strategies that might improve the accuracy and timely availability of the immuni-
zation histories of patients include . . . (Indicate all that are true.)
A. routine questionnaires administered to parents.
B. peel-off identification stickers on vaccine vials for use in medical charts.
C. barcodes on vaccine packaging, which are then scanned into medical records
systems.
D. confidential reporting and access to immunization registries.
9. Indicate the setting where you work.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
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D. Managed care organization.
E. Academic institution.
F. Other.
10. Which best describes your professional activities?
A. Family practice/general medicine.
B. Pediatrics.
C. Laboratory/pharmacy.
D. Immunization clinic.
E. Administration/research.
F. Other.
11. I plan to use these guidelines as the basis for . . . (Indicate all that are true.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
12. Each month, approximately how many patients/clients requiring vaccinations
do you treat?
A. None.
B. 1–5.
C. 6–15.
D. 16–25.
E. ≥26.
13. How much time did you spend reading this report and completing the exam?
A. ≤1 hour.
B. >1 hour but <2 hours.
C. ≥2 hours but <3 hours.
D. ≥3 hours.
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14. Overall, this report met the stated objectives.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
15. The tables and figure are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
16. Overall, the presentation of the report enhanced my ability to understand the
  material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
     
  Answer guide for questions 1–8
  1.c,d; 2.b,c,d; 3.b; 4.a,b,c; 5.b,d; 6.c; 7.a,b,d; 8.b,c,d
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immunization schedule (1,2 ). Potential advantages of stocking a limited number of
vaccines include reducing a) confusion and potential errors when staff must handle
redundant products and formulations, b) wastage when less commonly used prod-
ucts expire, c) cold storage capacity requirements, and d) administrative overhead in
accounting, purchasing, and handling.
EXTRA DOSES OF VACCINE ANTIGENS
Using combination vaccines containing some antigens not indicated at the time of
administration to a patient might be justified when a) products that contain only the
needed antigens are not readily available or would result in extra injections and b)
potential benefits to the child outweigh the risk of adverse events associated with the
extra antigen(s). An extra dose of many live-virus vaccines and Hib or HepB vaccines
has not been found to be harmful. However, the risk of adverse reactions might in-
crease when extra doses are administered earlier than the recommended interval for
certain vaccines (e.g., tetanus toxoid vaccines and pneumococcal polysaccharide vac-
cine) (23,50 ).
General Immunization Practice
Patients commonly receive extra doses of vaccines or vaccine antigens for diseases
to which they are immune. For example, some children receiving recommended sec-
ond or third doses of many vaccines in the routine immunization series will already
have immunologic protection from previous dose(s). Because serologic testing for
markers of immunity is usually impractical and costly, multiple doses for all children
are justified for both clinical and public health reasons to decrease the number of sus-
ceptible persons, which ensures high overall rates of protection in the population.
Extra vaccine doses also are sometimes administered when an immunization
provider is unaware that the child is already up-to-date for some or all of the antigens
in a vaccine (see Improving Immunization Records). During National Immunization
Days and similar mass campaigns, millions of children in countries around the world
are administered polio vaccine (51,52 ) and/or measles vaccine (53,54 ), regardless of
prior vaccination status.
Extra Doses of Combination Vaccine Antigens
ACIP, AAP, and AAFP recommend that combination vaccines may be used when-
ever any components of the combination are indicated and its other components are
not contraindicated (1,2 ). An immunization provider might not have vaccines avail-
able that contain only those antigens indicated by a child’s immunization history.
Alternatively, the indicated vaccines might be available, but the provider nevertheless
might prefer to use a combination vaccine to reduce the required number of injec-
tions. In such cases, the benefits and risks of administering the combination vaccine
with an unneeded antigen should be compared.
Live-Virus Vaccines
Administering an extra dose of live, attenuated virus vaccines to immunocompe-
tent persons who already have vaccine-induced or natural immunity has not been
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demonstrated to increase the risk of adverse events. Examples of these include MMR,
varicella, rotavirus, and oral polio vaccines.
Inactivated Vaccines
When inactivated (killed) or subunit vaccines (which are often adsorbed to alumi-
num-salt adjuvants) are administered, the reactogenicity of the vaccine must be
considered in balancing the benefits and risks of extra doses. Because clinical experi-
ence suggests low reactogenicity, an extra dose of Hib or HepB vaccine may be
administered as part of a combination vaccine to complete a vaccination series for
another component of the combination. Administration of extra doses of tetanus
toxoid-containing vaccines earlier than the recommended intervals can increase the
risk of hypersensitivity reactions (55–61 ). Examples of such vaccines include DTaP,
DTaP-Hib, diphtheria and tetanus toxoids for children (DT), tetanus and diphtheria
toxoids for adolescents and adults (Td), and tetanus toxoid (TT). Extra doses of teta-
nus toxoid-containing vaccines might be appropriate in certain circumstances,
including for children who received prior DT vaccine and need protection from pertus-
sis (in DTaP) or for immigrants with uncertain immunization histories.
Impact of Reimbursement Policies
Administering extra antigens contained in a combination vaccine, when justified as
previously described, is acceptable practice and should be reimbursed on the patient’s
behalf by indemnity health insurance and managed-care systems. Otherwise, high
levels of timely vaccination coverage might be discouraged.
Conjugate Vaccine Carrier Proteins
Some carrier proteins in existing conjugated Hib vaccines (62 ) also are used as
conjugates in new vaccines in development (e.g., for pneumococcal and meningococ-
cal disease) (63 ). Protein conjugates used in Hib conjugate vaccines include a mutant
diphtheria toxin (in HbOC), an outer membrane protein from Neisseria meningitidis
(in PRP-OMP), and tetanus and diphtheria toxoids (in PRP-T and PRP-D [polyribosyl-
ribitol phosphate polysaccharide conjugated to a diphtheria toxoid], respectively).
Administering large amounts of tetanus toxoid carrier protein simultaneously with
PRP-T conjugate vaccine has been associated with a reduction in the response to PRP
(64 ) (see Future Research and Priorities).
IMPROVING IMMUNIZATION RECORDS
Improving the convenience and accuracy of transferring vaccine-identifying infor-
mation into medical records and immunization registries should be a priority for
immunization programs. Priority also should be given to ensuring that providers have
timely access to the immunization histories of their patients.
As new combination vaccines with longer generic names and novel trade names
are licensed (Appendix A), problems with accurate recordkeeping in medical charts
and immunization registries will likely be exacerbated.
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Monitoring Vaccine Safety, Coverage, and Efficacy
All health-care providers are mandated by law to document in each patient’s medi-
cal record the identity, manufacturer, date of administration, and lot number of certain
specified vaccines, including most vaccines recommended for children (65,66 ). Al-
though such data are essential for surveillance and studies of vaccine safety, efficacy,
and coverage, these records are often incomplete and inaccurate. Two major active
(67 ) and passive (68,69 ) surveillance systems monitoring vaccine safety in the United
States have detected substantial rates of missing and erroneous data (≥10%) in the
recording of vaccine type, brand, or lot number in the medical records of vaccine re-
cipients (CDC, unpublished data, 1997). Similar rates of incomplete and incorrect
vaccination medical records were encountered by the National Immunization Survey
and the National Health Interview Survey (CDC, unpublished data, 1997).
Patient Migration Among Immunization Providers
Changing immunization providers during the course of a child’s vaccination series
is common in the United States. The 1994 National Health Interview Survey docu-
mented that approximately 25% of children were vaccinated by more than one
provider during the first 2 years of life (CDC, unpublished data, 1997). Eligibility for
Medicaid and resulting enrollment in Medicaid managed-care health plans tend to be
sporadic, with an average duration of 9 months and a median of <12 months in 1993
(Health Care Financing Administration, unpublished data, 1998).
The vaccination records of children who have changed immunization providers are
often unavailable and incomplete. Missing or inaccurate information regarding the
vaccines received previously might preclude accurate determination of which vac-
cines are indicated at the time of a visit, resulting in the administration of extra doses.
Strategies for Accurate Vaccine Identification
Potential strategies to improve the accuracy and timely availability of vaccination
information include the following:
• Designing and adopting a recommended, nationally standardized, uniform vacci-
nation medical record form. A copy provided to parents could serve as a record
of vaccination history for subsequent immunization providers and satisfy school
entry requirements. Immunization registries could generate printouts to docu-
ment vaccinations received from multiple providers and to replace misplaced
forms.
• Expanding and coordinating immunization registries, which track vaccinations
received by children and make the information available in a convenient and
timely manner to parents and authorized immunization providers with a need to
know, while protecting confidentiality and privacy.
• Developing technologies, standards, and guidelines to improve the accuracy and
convenience of recording and transferring information from the vaccine package
or vial into a patient’s medical record, compatible with both manual and comput-
erized medical record systems. These methods could include standardized,
peel-off identification stickers on vaccine packaging and standardized coding of
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vaccine identity, expiration date, and lot number. Machine-readable bar codes
following Uniform Code Council standards (70 ) on vaccine packaging and/or
stickers could facilitate accurate electronic transfer of this information into com-
puterized medical record systems and immunization registries.
FUTURE RESEARCH AND PRIORITIES
Further efforts are needed to study and obtain more data on the following key sub-
jects related to combination vaccines:
• The interchangeability of vaccines produced by different manufacturers to pre-
vent the same disease, particularly those that differ in the nature or quantity of
one or more component antigens.
• The safety and efficacy of administering combination vaccines to patients who
might already be fully immunized for one or more of the components.
• Economic and operations research on a) the frequency of delayed or missed vac-
cinations because of objections to multiple injections; b) the costs of any
increased disease burden caused by such missed vaccinations; c) the costs of
extra visits needed to comply with the routine immunization schedule; and d) the
administrative overhead and cost of errors and confusion that might result when
handling a greater number of products.
• The effects on immunogenicity and safety of simultaneous or repeated expo-
sures to the same proteins used as antigens (e.g., tetanus and diphtheria toxoids)
and/or as carrier components in existing and future conjugated vaccines.
• Research to develop and evaluate alternative means of antigen delivery by the
mucosal (71,72 ), parenteral (73 ), and cutaneous routes (74–77 ), which would
allow new and existing vaccines to be administered less painfully and more
safely than with needles and syringes (78–80 ).
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Existing Combination Vaccines in the United States, March 1999
Potential Combination Vaccines
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DTaP IPV
DTaP PnuCon
DTaP MenCon
Hib PnuCon
Hib MenCon
HepB HepA
IPV PnuCon
PnuConMenCon
DTaP HepB
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DTaP Hib PnuCon
Hib
DTaP PnuConMenCon
HepBHib IPV
PnuConMenConHib
HepB IPVHibDTaP
PnuConMenConHib IPV
PnuConMenConHibDTaP
HibDTaP HepB
1946
1947
1953
1955
1963
1970
1971
1971
1973
1975
1979
1991
1993
1996
1996
1998
DTwP
Rub
Rub
M R
Me Mu
DTwP
DTaP
Hib
Hib
HepB
Rv
HepAIPV
†
1945 INF
COMBINATION VACCINES*
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* Combination vaccines are defined as those containing multiple antigens to prevent different
diseases or to protect against multiple strains of infectious agents causing the same disease.
Existing combination vaccines are listed according to the year they were first licensed in the
United States. Potential combination vaccines are listed in order of their number of compo-
nents. Horizontal lines connect multiple antigens combined into one vaccine. Vertical alignment
illustrates how antigens may be joined in different combinations.
†As of publication date, some vaccine combinations listed are not licensed or approved for all
ages in the United States.
Adapted from: Weniger BG, Chen RT, Jacobson SH, et al. Addressing the challenges to immu-
nization practice with an economic algorithm for vaccine selection. Vaccine 1998;16:1885–97.
Sources: Mitchell VS, Philipose NM, Sanford JP, eds. The Children’s Vaccine Initiative: achieving
the vision. Washington, DC. National Academy Press, 1993.
Grabenstein JD, ImmunoFacts: vaccines and immunologic drugs. St. Louis: Facts and Compari-
sons, August 1998.
Abbreviations: DT=diphtheria and tetanus toxoids vaccine (for children); DTaP=diphtheria and
tetanus toxoids and acellular pertussis vaccine; DTaP-Hib=diphtheria and tetanus toxoids and
acellular pertussis and Haemophilus influenzae type b vaccine; DTwP=diphtheria and tetanus
toxoids and whole-cell pertussis vaccine; DTwP-Hib=diphtheria and tetanus toxoids and whole-
cell pertussis and Haemophilus influenzae type b vaccine; HepA=hepatitis A vaccine; HepB=
hepatitis B vaccine; Hib=Haemophilus influenzae type b conjugate vaccine; Hib-HepB=
Haemophilus influenzae type b and hepatitis B vaccine; Hib-HepB-IPV=Haemophilus influenzae
type b, hepatitis B, and trivalent inactivated polio vaccine; INF=influenza vaccine; IPV=trivalent
inactivated polio vaccine (killed Salk type); Me=measles vaccine; Me-Mu=measles and mumps
vaccine; Me-Rub=measles and rubella vaccine; MenCon=meningococcal (Neisseria meningitidis)
conjugate vaccine; MenPS=meningococcal (Neisseria meningitidis) polysaccharride vaccine;
MMR=measles-mumps-rubella vaccine; MMR-Var=measles-mumps-rubella and varicella (chick-
enpox) vaccine; Mu=mumps vaccine; Mu-Rub=mumps and rubella vaccine; OPV=trivalent oral
polio vaccine (live Sabin type); PnuCon=pneumococcal (Streptococcus pneumoniae) conjugate
vaccine; PnuPS=pneumococcal (Streptococcus pneumoniae) polysaccharide vaccine;  Rv=rota-
virus vaccine; Rub=rubella vaccine; Td=tetanus and diphtheria toxoids vaccine (for adolescents
and adults).
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Appendix B
Recommendation
Strength
of evidence Comment
Preference for Combination Vaccines B Parent and provider surveys
Manufacturer Interchangeability
Permissible:
Diphtheria†, Tetanus†, Hib, HepB A Good evidence
HepA B Preliminary data
Discouraged:
Acellular pertussis (in DTaP, DTaP-Hib) C Little or no evidence
Vaccine Supply C
Extra Doses of Vaccine Antigens
Permissible:
HepB, Hib, MMR, OPV, Rv, Var A Little or no risk of adverse events
 for those already immune
Cautioned:
Tetanus† B Frequent revaccination could cause
 hypersensitivity reactions
EVIDENCE FOR RECOMMENDATIONS*
*Principal recommendations are classified by the strength and quality of evidence supporting
them according to principles described elsewhere (a,b ), using categories adapted from pre-
vious publications (c,d ).
 A=Strong epidemiologic evidence (i.e., at least one properly randomized, controlled trial)
 and/or substantial clinical or public health benefit.
 B=Moderate epidemiologic evidence (i.e., at least one well-designed clinical trial without
 randomization, or cohort or case-controlled analytic studies, preferably from more than one
 center) and/or moderate clinical or public health benefit. 
 C=Epidemiologic evidence minimal or lacking; recommendation supported by the opinions
 of respected authorities based on clinical and field experience, descriptive studies, or reports
 of expert committees.
†Vaccines containing diphtheria toxoids and tetanus toxoids include DT, Td, DTaP, DTwP, DTaP-
Hib, and DTwP-Hib. TT contains tetanus toxoid only.
Abbreviations: DT=diphtheria and tetanus toxoids vaccine (for children); DTaP=diphtheria and
tetanus toxoids and acellular pertussis vaccine; DTaP-Hib=diphtheria and tetanus toxoids and
acellular pertussis and Haemophilus influenzae type b vaccine; DTwP=diphtheria and tetanus
toxoids and whole cell pertussis vaccine; DTwP-Hib=diphtheria and tetanus toxoids and whole
cell pertussis and Haemophilus influenzae  type b vaccine; HepA=hepatitis A vaccine;
HepB=hepatitis B vaccine; Hib=Haemophilus influenzae type b conjugate vaccine; MMR=mea-
sles-mumps-rubella vaccine; OPV=trivalent oral polio vaccine (live Sabin type); Rv=Rotavirus
vaccine. Td=tetanus and diphtheria toxoids vaccine (for adolescents and adults); Var=varicella
(chickenpox) vaccine.
Sources:
a. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases.
Infectious Diseases Society of America. Clin Infect Dis 1994;18:421.
b.Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine:
what it is and what it isn’t [Editorial]. BMJ 1996;312:71-2.
c. CDC. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR 1997;46(No. RR-8):1-24.
d.CDC. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons
infected with human immunodeficiency virus. MMWR 1997;46(No. RR-12):1-46.
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